7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,605.54

+564.15

+0.73%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

OTC Markets OTCPK - Delayed Quote USD

Revive Therapeutics Ltd. (RVVTF)

0.0140 -0.0010 (-6.67%)

At close: October 30 at 4:00:00 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases

ACCESS Newswire 1mo ago

RVV.CN

31R.F

RVVTF
-6.67%
Revive Therapeutics Announces Proposed Shares for Debt Settlement

ACCESS Newswire 2mo ago

RVV.CN

RVVTF
-6.67%
31R.F
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio

ACCESS Newswire 2mo ago

RVV.CN

RVVTF
-6.67%
31R.F
Revive Therapeutics Reports Grant of Options

ACCESS Newswire 2mo ago

RVV.CN

RVVTF
-6.67%
31R.F
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study

ACCESS Newswire 2mo ago

RVV

RVVTF
-6.67%
31R.F
Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

ACCESS Newswire 3mo ago

RVV.CN

31R.F

RVVTF
-6.67%
Revive Therapeutics Announces Proposed Private Placement

ACCESS Newswire 4mo ago

RVV.CN

31R.F

RVVTF
-6.67%
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures

ACCESS Newswire 5mo ago

RVV.CN

31R.F

RVVTF
-6.67%
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

GlobeNewswire 10mo ago

RVVTF
-6.67%

Performance Overview

Return	RVVTF	S&P/TSX Composite index (^GSPTSE)
YTD	+75.00%	+11.78%
1-Year	+40.00%	+18.03%
3-Year	-41.67%	+88.90%

Mobilize your Website

View Site in Mobile | Classic

Share by: